Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MXCT
Upturn stock ratingUpturn stock rating

MaxCyte Inc (MXCT)

Upturn stock ratingUpturn stock rating
$2.18
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: MXCT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $7

1 Year Target Price $7

Analysts Price Target For last 52 week
$7Target price
Low$2
Current$2.18
high$5.2

Analysis of Past Performance

Type Stock
Historic Profit -21.82%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 234.12M USD
Price to earnings Ratio -
1Y Target Price 7
Price to earnings Ratio -
1Y Target Price 7
Volume (30-day avg) 6
Beta 0.3
52 Weeks Range 2.00 - 5.20
Updated Date 06/30/2025
52 Weeks Range 2.00 - 5.20
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.4

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Earnings Date

Report Date 2025-06-11
When After Market
Estimate -0.13
Actual -0.1

Profitability

Profit Margin -110.92%
Operating Margin (TTM) -118.34%

Management Effectiveness

Return on Assets (TTM) -13.12%
Return on Equity (TTM) -19.63%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 113389585
Price to Sales(TTM) 6.21
Enterprise Value 113389585
Price to Sales(TTM) 6.21
Enterprise Value to Revenue 3.01
Enterprise Value to EBITDA -11.07
Shares Outstanding 106319000
Shares Floating 95138075
Shares Outstanding 106319000
Shares Floating 95138075
Percent Insiders 1.45
Percent Institutions 75.79

Analyst Ratings

Rating 3
Target Price 7
Buy -
Strong Buy 6
Buy -
Strong Buy 6
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

MaxCyte Inc

stock logo

Company Overview

overview logo History and Background

MaxCyte Inc. was founded in 1998. The company pioneered flow electroporation technology and has focused on enabling cell-based research, development, and manufacturing of innovative cell therapies.

business area logo Core Business Areas

  • ExPERT Platform: The core technology platform. It is a flow electroporation technology that enables complex cell engineering for cell therapy and drug discovery. Provides delivery of a wide range of molecules into cells. Revenue model involves sales of instruments, disposables, and service contracts.
  • CARMA Platform: CARMA is MaxCyte's own cell therapy development pipeline, with a focus on targeting difficult-to-treat cancers. While not the primary revenue driver currently, it represents future potential.
  • Strategic Partnerships: MaxCyte partners with leading biopharmaceutical companies, granting them access to its technology through Strategic Platform Licenses (SPLs). These licenses generate recurring revenue via milestone payments and royalties on sales of therapies developed using the MaxCyte platform.

leadership logo Leadership and Structure

Doug Doerfler is the President and CEO. The company has a typical corporate structure with departments for R&D, manufacturing, sales, marketing, and finance.

Top Products and Market Share

overview logo Key Offerings

  • ExPERT Platform: Flow electroporation technology enabling cell engineering. MaxCyte holds a strong position in this niche market, but specific market share data is challenging to obtain. Competitors include Lonza, Thermo Fisher Scientific (although they do not compete directly), and smaller companies developing alternative transfection methods. Revenue from this is in form of sale of the instruments and the associated supplies for usage.
  • Strategic Platform Licenses (SPLs): Allows partners to use MaxCyte's technology to develop their cell therapies. Revenue is generated from upfront payments, milestone payments, and royalties on sales of approved therapies. No direct competitor in this field. Strategic platform licenses include BMS, CRISPR Therapeutics, Vertex, and others.

Market Dynamics

industry overview logo Industry Overview

The cell therapy and gene editing industries are experiencing rapid growth, driven by advances in technology and increasing demand for novel treatments for cancer and other diseases.

Positioning

MaxCyte is positioned as a key enabling technology provider for cell therapy development. Its flow electroporation technology offers advantages in terms of efficiency, scalability, and cell viability, giving it a competitive edge.

Total Addressable Market (TAM)

The cell therapy market is projected to reach billions of dollars in the coming years. MaxCyte is positioned to capture a significant portion of this market by providing its technology to leading cell therapy developers.

Upturn SWOT Analysis

Strengths

  • Proprietary and differentiated technology (flow electroporation)
  • Strong intellectual property portfolio
  • Established partnerships with leading biopharmaceutical companies
  • Recurring revenue stream from SPLs
  • CARMA internal therapeutic development pipeline

Weaknesses

  • Reliance on partners' success for royalty revenue
  • CARMA development is in early stages and has high risk
  • Cash burn rate and potential need for future financing
  • Competition from alternative transfection technologies

Opportunities

  • Expansion of SPL partnerships
  • Advancement of CARMA pipeline
  • Increasing adoption of cell therapies
  • Development of new applications for flow electroporation
  • Market growth in gene editing

Threats

  • Clinical trial failures of partners' cell therapies
  • Emergence of competing transfection technologies
  • Regulatory challenges in the cell therapy space
  • Economic downturn impacting biopharmaceutical R&D spending
  • Intellectual property infringement

Competitors and Market Share

competitor logo Key Competitors

  • LON: LNZ
  • TMO

Competitive Landscape

MaxCyte has a strong position in flow electroporation, offering advantages over traditional methods. Competition exists from companies developing alternative transfection technologies, but MaxCyte's established partnerships and proprietary technology provide a competitive edge.

Growth Trajectory and Initiatives

Historical Growth: MaxCyte has shown significant growth in revenues over the years, driven by SPL agreements. However, revenue can fluctuate depending on partner milestones.

Future Projections: Analyst projections anticipate continued revenue growth driven by new SPLs, milestone payments, and potential royalties from approved therapies. However, there are uncertainties linked to regulatory approvals and clinical outcomes.

Recent Initiatives: Recent initiatives include new partnerships, advancement of the CARMA pipeline, and expansion of the ExPERT platform.

Summary

MaxCyte is a promising biotechnology company focused on enabling cell-based therapies through its flow electroporation technology. Its strength lies in the strategic partnerships and recurring revenue, but the dependence on the success of its partners and the cash burn rate are weaknesses. The company needs to carefully monitor its cash usage and expand its application of its Expert platform. The growth projections are optimistic, but the market has its own challenges.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • MaxCyte Inc. SEC Filings, Investor Presentations, Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share data is based on estimations and industry reports. Past performance is not indicative of future results.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About MaxCyte Inc

Exchange NASDAQ
Headquaters Rockville, MD, United States
IPO Launch date 2021-07-30
President, CEO & Executive Director Mr. Maher Masoud
Sector Healthcare
Industry Medical Devices
Full time employees 114
Full time employees 114

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.